Aaron N. Hata
Impact in
- Oncology top 0.5%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Cancer Research top 0.5%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 51
- Lung Cancer Research Studies 22
- Cancer-related Molecular Pathways 7
-
- Cancer Genomics and Diagnostics 21
- Co-authors
- RICHARD M. BREYER (7 shared papers)Jeffrey A. Engelman (8 shared papers)Anthony C. Faber (5 shared papers)Heidie Frisco Cabanos (2 shared papers)Justin F. Gainor (10 shared papers)Ibiayi Dagogo‐Jack (8 shared papers)Mari A. Mino-Kenudson (11 shared papers)Jochen K. Lennerz (6 shared papers)
- Journals
- Cancer Discovery (13 papers)Clinical Cancer Research (10 papers)Journal of Thoracic Oncology (9 papers)Cancer Research (5 papers)Nature Medicine (5 papers)
- Partner nations
- United StatesJapanGermany
In The Last Decade
Aaron N. Hata
112 papers receiving 11.2k citations
Aaron N. Hata's Hit Papers
Peers
Comparison fields: 5 of 136
- Oncology 4.7k
- Cancer Research 2.3k
- Pulmonary and Respiratory Medicine 4.0k
- Molecular Biology 5.3k
- Immunology 978
Countries citing papers authored by Aaron N. Hata
This map shows the geographic impact of Aaron N. Hata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aaron N. Hata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aaron N. Hata more than expected).
Fields of papers citing papers by Aaron N. Hata
This network shows the impact of papers produced by Aaron N. Hata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aaron N. Hata. The network helps show where Aaron N. Hata may publish in the future.
Co-authors
The 25 scholars most cited alongside Aaron N. Hata, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 113 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis Hit paper breakdown → | 2016 | 1058 |
| 2 | Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition Hit paper breakdown → | 2016 | 775 |
| 3 | Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune modulation Hit paper breakdown → | 2004 | 701 |
| 4 | The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics Hit paper breakdown → | 2015 | 520 |
| 5 | A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors Hit paper breakdown → | 2020 | 491 |
| 6 | Heterogeneity Underlies the Emergence of EGFR T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor Hit paper breakdown → | 2015 | 424 |
| 7 | Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation Hit paper breakdown → | 2021 | 403 |
| 8 | The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution Hit paper breakdown → | 2020 | 375 |
| 9 | Landscape of Acquired Resistance to Osimertinib in EGFR -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion Hit paper breakdown → | 2018 | 371 |
| 10 | Cycling cancer persister cells arise from lineages with distinct programs Hit paper breakdown → | 2021 | 334 |
| 11 | 2012 | 331 | |
| 12 | 2018 | 272 | |
| 13 | 2018 | 248 | |
| 14 | 2017 | 233 | |
| 15 | 2018 | 215 | |
| 16 | 2021 | 204 | |
| 17 | 2019 | 192 | |
| 18 | 2020 | 183 | |
| 19 | 2019 | 175 | |
| 20 | 2018 | 173 |
About Aaron N. Hata
Aaron N. Hata is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Molecular Biology and Immunology, having authored 113 papers that have together received 11.4k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (45 papers), Lung Cancer Research Studies (22 papers), Cancer Genomics and Diagnostics (21 papers), Cancer therapeutics and mechanisms (18 papers), RNA modifications and cancer (9 papers), PI3K/AKT/mTOR signaling in cancer (8 papers), Cancer-related Molecular Pathways (7 papers) and Cell death mechanisms and regulation (6 papers). The work is most often cited by research in Oncology (4.7k citations), Cancer Research (2.3k citations), Pulmonary and Respiratory Medicine (4.0k citations), Molecular Biology (5.3k citations) and Immunology (978 citations). Aaron N. Hata has collaborated with scholars based in United States, Japan and Germany. Frequent co-authors include RICHARD M. BREYER, Jeffrey A. Engelman, Anthony C. Faber, Heidie Frisco Cabanos, Justin F. Gainor, Ibiayi Dagogo‐Jack, Mari A. Mino-Kenudson, Jochen K. Lennerz, Alice Tsang Shaw and Catherine Belle Meador. Their work appears in journals such as Cancer Discovery, Clinical Cancer Research, Journal of Thoracic Oncology, Cancer Research and Nature Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.